The Cigna Group’s Stock Price Drops to $315.74, Marking a 5.31% Decline – Find Out What’s Impacting CI’s Market Performance

The Cigna Group (CI)

315.74 USD -17.72 (-5.31%) Volume: 3.56M

The Cigna Group’s stock price is currently standing at 315.74 USD, experiencing a decline of -5.31% this trading session with a trading volume of 3.56M, yet still showcasing a positive year-to-date (YTD) performance with a percentage change of +14.34%.

Latest developments on The Cigna Group

Today, Cigna Group stock price took a hit, with shares down by 6.47% on May 12. This decline comes as President Trump targets ‘drug middlemen’ in an executive order aimed at lowering drug prices, affecting not only Cigna but also CVS. Additionally, Cigna is facing a proposed class action lawsuit over online tracking pixels. Despite this, Truist Securities raised the price target for Cigna Group, which could impact the stock moving forward. The company’s stock movement is also being influenced by proposed changes to Medicaid. In a separate incident, Cigna made headlines for denying an operation to a man battling lung cancer, sparking controversy and potentially impacting the company’s reputation.

The Cigna Group on Smartkarma

Analysts at Baptista Research on Smartkarma have provided bullish coverage on Cigna Group, highlighting strategic growth and capital investments as key drivers of optimism. The company’s fourth-quarter and full-year 2024 financial results showed a mixed performance, with revenue increasing by 27% to approximately $247 billion. Despite adjusted earnings per share (EPS) rising by 9% to $27.33, below expectations, indicating some pressure on profitability.

Furthermore, Baptista Research‘s analysis of Cigna Corporation emphasized its specialty market position and biosimilars strategy as major drivers of bullishness. The company’s third-quarter 2024 earnings revealed shareholders’ net income of $739 million or $2.63 per share, although this figure was impacted by a significant non-cash after-tax net realized investment loss of $1 billion related to VillageMD. This write-down of assets and impairment charge has been excluded from adjusted operating income and earnings per share calculations.

A look at The Cigna Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Cigna Group seems to have a positive long-term outlook. With high scores in Value and Dividend, the company appears to be a solid investment choice for those looking for stable returns. Additionally, the Momentum score suggests that Cigna Group is currently performing well in the market, which could indicate future growth potential.

Although the Growth and Resilience scores are not as high as Value and Dividend, they still indicate that Cigna Group is positioned to weather challenges and potentially expand its market presence. Overall, the combination of these scores paints a picture of a company that is well-established in the insurance industry and has the potential for continued success in the future.

### The Cigna Group operates as an insurance company. The Company offers life, accident, disability, supplemental, medicare, and dental insurance products and services. The Cigna Group serves individuals, families, and businesses worldwide. ###

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma